Member Info for DugWalker

@NickE

The company made a very significant move to improve its sales/marketing capabilities when it recruited a highly respected and successful marketing director (Steve Aribo) shortly after the launch of the PSE test.

Happy New Year GMS.

I'm hopeful you will be pleasantly surprised with the sales data for CiRT and PSE.

CiRT was starting to grow at an exponential rate, albeit from a low base, when figures were last provided. I have looked at that data and extrapolated using a very conservative linear growth rate estimate of 20% per month. I would hope to be hitting 250 CiRT by end of the 2023 calender year. Remember too that the BUPA agreement came after the last sales data was made available. I expect BUPA to be encouraging their oncologists to make good use of CiRT as it will save them huge sums spent on ineffective immunotherapy treatments. I would expect maybe 5 to 10 CiRT tests per month for UK BUPA patients alone.

It may be too early to see big numbers of PSE sales as the Medicare and Medicaid reimbursement codes have only been live since Jan 1st. We do know that the urologist running the prostate health podcast has been using PSE for his patients and promoting it via his podcast. The new state legislation in NewYork requiring insurers to make biomarker tests available to their clients is a timely boost to the prospects of PSE flying out of the traps.

I'm more than hopeful we will see OBD become profit making this year and expect the SP to be well into 3 figures by this time next year.

Not uncommon to see buys showing as sells recently Dave. MM 's have had the ask and bid prices all over the shop leading to many buys below the mid price.

Https://us02web.zoom.us/webinar/register/7417006471039/WN_ZqpvQz8hQOKMufXOKPwH1A#/registration

Sorry link.for webinar registration above.

Just two weeks away and should be more than interesting. Expect updates on CiRT sales and early indications of PSE launch success and BUPA partnership in UK amongst other advances

Don't forger to register here;

Just over 2 working weeks before we get updates on CiRT and PSE sales progress. With CiRT having hit close to £200k a month revenues 6 months ago I would expect the update to show revenues and profits taking OBD very close to eliminating operating losses and hopefully signalling a transition to profitability in 2024.

The news on state legislation in New York requiring insurers to ensure biomarker technology is available to all cancer patients is a timely boost coming as it does, with the episwitch PSE code going live from 1st Jan. A big year ahead so happy new year to shareholders and GLA for a transformational year ahead.

Just took a small top up at 28.9 p which is just below mid point of offer/bid. Hence showing as a sell when it is a buy.

Always good to have a keen eye on OBD's academic publications. They do give emphasis to how episwitch converts to health service benefits in the form of idiagnostics, efficacy and targetting of treatments and cost savings for health services. Massive potential here.

I suppose anything is possible, but the company focus is very much on continued growth of CiRT sales and the launch of PSE. To that end they raised some funds last year to upgrade the labs. I would expect these activities to remain as the clear priorities as they should see OBD transform to profit making in the near future. It is good to have a well stocked product pipeline that promises future growth, but I am sure the management are concious of the risks of overstretching the resources to the detriment of ongoing commercialisation programmes. I think it would be hard to justify an imminent fund raise and as far as I'm aware talk of one is baseless and pure speculation.

As for forward selling, it was roundly beaten yesterday by forward buying in anticipation of positive newsflow through Q1 next year. With the host of the US prostate health podcast confirming he has bought PSE tests for his patients and with BUPA reimbursement of CiRT in the UK we should expect good news!

Down the line I'd consider participating in future raises should they be needed and if the opportunity arises. Personally I'd be surprised if the selling yesterday was anything other than profit taking on the rising share price and I hope we will see further rises today.

The penultimate trade a few minutes earlier was a buy of a few hundred shares at 29.5. Its hard to imagine. The only way I can see a big volume trading minutes later at 30p would be as a buy, unless the MM's are desperate to accumulate some for an even bigger buy order.

Regardless a good day today and I expect there's quite a few more like it to come in the near term future.

The PHI index combines three measurements of PSA in an attempt to improve the predictive benefit of PSA measurements.

Https://pubmed.ncbi.nlm.nih.gov/37204514/

The improvements appear to be small and incremental relative to a conventional PSA test. Of course we know there are numerous reasons why someones PSA increases so that it is perhaps not surprising that heard much about PHI even though it has been around for ten years or so.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663012/

Been slowly building some upward momentum following a period of consolidation. This morning's RNS confirms we really only have 2 working weeks of trading before the annual results. That should signal another period of positive news that could see us reach a new ATH.

I expect the first couple of months to:

-update CiRT sales for the last 6 months (coincident with annual results)

-update PSE sales since the launch.

-forward projections to highlight potential for near term transformation to profitability.

-show rapid growth of PSE as medicare/Medicaid

reimbursement code goes live Jan 1st.

-announce completion of lab upgrades.

- show first significant benefits of recent recruitment (e.g. hospital group contracts for PSE inthe US).

-Validation of one or two new tests (e.g. colerectol blood test).

-Announce OBD's role in the Transform prostate screening trial (leading candidate to become first technology adopted).

and that's just for starters.

5085

Nice find. Another example of the clinical benefits of OBD's new and powerful genomic technology. It is clear that Episwitch is a ground breaking diagnostic tool (e.g. Episwitch PSE for prostate cancer) but it is also a very effective screening tool capable of predicting how patients might respond if prescribed expensive cancer treatments. That must make OBD a potential takeover target for big pharma. The competitive advantage that a big drug producing company could derive from exclusive access to OBD's technology is massive. I think it may just be a matter of time before one of our big pharrma partnerships transitions to a straight offer to buy OBD. The potential for shareholders to get returns that are many multiples of their original investment is obvious. I expect to hang around here until the takeover potential becomes a reality.

Yep indeed it is Dibs. Thanks for trying to educate me though. At least I think I now understand why I have no clue as to what is happening with the SP!

I prefer your mid price between bid and ask as something I can relate to so I'm sticking to.that as the true SP currently.

Thanks Dibs. Guessed it was some kinda pricing anomaly but don't understand the details well enough to figure. Am I right to assume 'A trade' refers to auction?

Strange price action. Share price has been lower than the bid since market opened.

Good to hear the podcast host (a practicing urologist) confirm that he has bought tests for patients. Should serve as a nice heads up for other urologists in the US.

I believe ir means 'sellers beware'.

Https://twitter.com/SharePickers/status/1735258459350700366?t=rpskEWTdDREOHOVrGf-Ktw&s=19

This isn't a share for the impatient trader Kingalf. There are too many positive news stories coming down the pipeline making the risk of losing out high and the cost painful!

News of a new test e.g. colorectal or ALS could drop anytime.

January brings FY 23 preliminaries. Expect those to show reduced losses as CiRT and PSE revenues grow. Should also get updates on CiRT and PSE sales growth and that could well confirm a transformation to profit making later next year.

USA Medicare and Medicade reimbursement code for the PSE test goes live in Jan and should encourage a jump in PSE sales across the pond.

Lab upgrades are scheduled for completion in Jan. These are in anticipation of increased volumes of episwitch tests in the UK and the US.

The announcement of the UK prostate screening trial 'Transform' is due Q1 24. Participants and roles likely to confirms PSE as a strong candidate for a national prostate screening programme.

New agreements with BUPA should follow the CiRT reimbursement agreement. PSE a likely basis for such agreements.

All of the above would be considered as imminent positives in any market other than AIM.

I'm slowly accumulating as I see this pushing through 50p early '24 and above £1 by the end of the year. Of course should big Pharma fancy some inorganic growth OBD must be a candidate!

Well in Dibs!